Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy

Abstract EN

Serous ovarian cancer (SOC) is a significant cause of morbidity and mortality in females with poor prognosis because of advanced stage at presentation.

Recently, neoadjuvant chemotherapy (NACT) is being used for management of advanced SOC, but role of tissue biomarkers in prognostication following NACT is not well established.

The study was conducted on advanced stage SOC patients (n=100) that were treated either conventionally (n=50) or with NACT (n=50), followed by surgery.

In order to evaluate the expression of tissue biomarkers (p53, MIB1, estrogen and progesterone receptors, Her-2/neu, E-cadherin, and Bcl2), immunohistochemistry and semiquantitative scoring were done following morphological examination.

Following NACT, significant differences in tumor histomorphology were observed as compared to the native neoplasms.

MIB 1 was significantly lower in cases treated with NACT and survival outcome was significantly better in cases with low MIB 1.

ER expression was associated with poor overall survival.

No other marker displayed any significant difference in expression or correlation with survival between the two groups.

Immunophenotype of SOC does not differ significantly in samples from cases treated with NACT, compared to upfront surgically treated cases.

The proliferating capacity of the residual tumor cells is less, depicted by low mean MIB1 LI.

MIB 1 and ER inversely correlate with survival.